| Followers | 5 |
| Posts | 260 |
| Boards Moderated | 0 |
| Alias Born | 07/03/2025 |
Friday, February 27, 2026 4:24:09 PM
The science changed. How clinicians see the importance of triglycerides in cardiometabolic disease and how to treat CVD/Obesity/Metabolic Syndrome and Diabetes is better understood now. That’s why the Reduce it trial is so rich with data. They do secondary analysis on it for a reason. Reduce it has those patients in spades. Plus, most of that patient cohort is also in registry data and treatment improves with data. Now think why they are doing research with the GLP 1 drug and it gets clearer. Their posters and presentation at the ACC build credibility.
The other thing that’s finally understood here is the mode of action MOA. In 2019 when FDA approved for CVD they still didn’t understand how this drug worked. Their posters creation of the mineral oil issue is as suspect as the patent loss by Du. Today, we understand the MOA much better and can apply it to curing cardiovascular disease. Turns out decades of statin use and following the food pyramid doesn’t cure CVD. I won’t get into how statins got approved and the data used but you can research it.
The problem here is that clinicians need new marching orders and standards of care. The days of physicians prescribing a Fenofibrate/Fibrate are coming to an end. The ADA (Diabetes) now includes Vascepa as a standard of Care. Practice of Medicine is the real issue to go with the new science. FDA does not regulate the POM which is why the label change is a big deal. It’s their final word on the matter and they didn’t issue a Dear Doctor Letter for a reason because it’s so obviously bad medicine. A Doctor that wants to practice medicine, wrongly prescribing a drug that offers no CVD benefit will have to answer to it. They can explain why. Good luck. If I was an attorney I’d have a new business.
Now you just need to get PBM’s on board and the next owner of this drug can start negotiating with PBM’s playing that coupon and tier placement game with a variety of drugs. Amarin has demonstrated they have zero leverage in this game. Since 2013 they tried to go it alone and the system beat them down at our expense. The end of this European disaster and the FDC are over by the last regime. Barclays can help plot an exit. So can a CSG. They already have a facebook group and a share count. Now we just crowdfund it like we all did with that attorney to get in front of judges a few years back Retail investors have more leverage at our disposal. In fact, Bob Burrows and I had a nice conversation about it.
The other thing that’s finally understood here is the mode of action MOA. In 2019 when FDA approved for CVD they still didn’t understand how this drug worked. Their posters creation of the mineral oil issue is as suspect as the patent loss by Du. Today, we understand the MOA much better and can apply it to curing cardiovascular disease. Turns out decades of statin use and following the food pyramid doesn’t cure CVD. I won’t get into how statins got approved and the data used but you can research it.
The problem here is that clinicians need new marching orders and standards of care. The days of physicians prescribing a Fenofibrate/Fibrate are coming to an end. The ADA (Diabetes) now includes Vascepa as a standard of Care. Practice of Medicine is the real issue to go with the new science. FDA does not regulate the POM which is why the label change is a big deal. It’s their final word on the matter and they didn’t issue a Dear Doctor Letter for a reason because it’s so obviously bad medicine. A Doctor that wants to practice medicine, wrongly prescribing a drug that offers no CVD benefit will have to answer to it. They can explain why. Good luck. If I was an attorney I’d have a new business.
Now you just need to get PBM’s on board and the next owner of this drug can start negotiating with PBM’s playing that coupon and tier placement game with a variety of drugs. Amarin has demonstrated they have zero leverage in this game. Since 2013 they tried to go it alone and the system beat them down at our expense. The end of this European disaster and the FDC are over by the last regime. Barclays can help plot an exit. So can a CSG. They already have a facebook group and a share count. Now we just crowdfund it like we all did with that attorney to get in front of judges a few years back Retail investors have more leverage at our disposal. In fact, Bob Burrows and I had a nice conversation about it.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
